Skip to main content

UBS Sustainable Health Transformation Equity Fund

UBS Sustainable Health Transformation Equity Fund is an equity fund managed by UBS in the Sektor – Helse category.

About this fund

UBS Sustainable Health Transformation Equity Fund is an equity fund run by UBS, compared against the Sektor – Helse peer group.

Launched in 1998, it has 28 years behind it.

It ranks 5 out of 18 in its peer group on return so far this year measured in NOK as of 13.11.2026.

It is run by a team of 3.

The manager states a volatility of 15.0% for the fund.

The reference index is MSCI World Health Care (net div. reinv.).

Manager
UBS
Category
Sektor – Helse
Region
Global
Sector
Health Care
Style
Sector Focus
SFDR
Article 8
ISIN
LU0085953304
Inception
1998-05-27
Benchmark
MSCI World Health Care (net div. reinv.)
AUM
321 m USD
Returns
YTD 11.0% · 1Y 13.8% · 3Y 10.2% · 5Y 9.0%

Portfolio managers

Actively managedEquityGlobalHealth care
YTD Return · NOK
+11,0 %from NAV
Calculated NOK return from USD · A (USD) (NOK Calculated)
Last NAV 589,80 USD · 13 Nov 2026
Returns by period · NOK · net
ann. 3Y+
+11,0 %
YTD
+13,8 %
1y
+10,2 %
3y, annualised
+9,0 %
5y, annualised
+11,9 %
10y, annualised
Fund size
321,3 mill. USD
Total fund AUM
Management fee
1,63 %
Annual · class A
Ongoing charge
1,79 %
Annual · class A
Performance fee
None
Stated by the manager
Annual cost on platforms
1,40 %–1,42 %
Class A · 3 platforms · net of platform rebate, incl. platform fee, excl. transaction costs
SFDR
Article 8
Sustainability
Launched
May 1998
ISIN LU0085953304
BenchmarkMSCI World Health Care · Net
Risk
Volatility (stated by the manager)15,0 %
Sharpe Ratio0,43
Beta1,04
About the fund
The fund

UBS Sustainable Health Transformation Equity Fund is an actively managed healthcare equity fund with a track record going back to 1998. The management company is UBS Asset Management, the asset management division of the Swiss banking group UBS Group AG, headquartered in Zürich. The division offers both index and ETF products and active strategies.

Investment philosophy

The managers have a stated overweight in innovative small and mid-cap healthcare companies. They describe these as leaders in making healthcare more affordable, more accessible and less fragmented. The fund draws on the healthcare analysts in UBS's US intrinsic value equity team.

The managers

Matthew Konosky in Chicago has managed the fund since 2016. He is a senior analyst and portfolio manager in UBS's US intrinsic value equity team, joined UBS in 2006 from Sanford C. Bernstein, where he was a healthcare analyst, and was educated at MIT and NYU Stern. Responsibility is shared with biotech analyst Sarah Schram in Chicago, who holds a PhD in neuroscience, and Charlotte Harris in London. They are part of UBS's healthcare and biotech team and also manage UBS Biotech Equity Fund. Harris also manages UBS Small Caps Europe Equity Fund. Scott Wilkin, head of global equities at UBS, was a co-manager from 2016 until September 2026.

The portfolio

The portfolio has a large share in its largest positions and has fluctuated less than comparable funds. Alongside US companies such as Eli Lilly, UnitedHealth and Intuitive Surgical, European and Japanese companies such as AstraZeneca, Novartis, Sandoz, Alcon, Philips and Chugai Pharmaceutical recur.

FundTelligence description · 18/10/2026
Comparison basis: Ranked among 18 of 31 funds · 13 left out (5 share class outside the rule, 3 missing return, 1 return as of an earlier date, 1 history too short, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026

Portfolio managers

CH
Portfolio Manager
On the fund since Nov 28, 2025
MA
Portfolio Manager
On the fund since Aug 31, 2016
SA
Portfolio Manager
On the fund since Aug 28, 2026

Position in the peer group

Sector Health Care Equities · 31 funds in the peer group. The number ranked and the date are stated per period. 12 of them converted to NOK.

7 of 18 funds ranked on a calculated return

#5/ 18Year to date
+11.02% NOK

as of 13 Nov 2026 · Converted from USD to NOK

About the figures

13 of 31 funds in the group hold no figure for the date and are not counted. 1 funds with older figures: up to 5 business days.

#6/ 221 year
+14.17% NOK

as of 13 Nov 2026 · Converted from USD to NOK

About the figures

9 of 31 funds in the group hold no figure for the date and are not counted. 1 funds with older figures: up to 5 business days.

#3/ 223 years (ann.)
+10.27% NOK

as of 13 Nov 2026 · Converted from USD to NOK

About the figures

9 of 31 funds in the group hold no figure for the date and are not counted. 1 funds with older figures: up to 5 business days.

#3/ 225 years (ann.)
+8.96% NOK

as of 13 Nov 2026 · Converted from USD to NOK

About the figures

9 of 31 funds in the group hold no figure for the date and are not counted. 1 funds with older figures: up to 5 business days.

Comparison basis

Year to date

Comparison basis: Ranked among 18 of 31 funds · 13 left out (5 share class outside the rule, 3 missing return, 1 return as of an earlier date, 1 history too short, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026

1 year

Comparison basis: Ranked among 22 of 31 funds · 9 left out (4 missing return, 2 return as of an earlier date, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026

3 years (ann.)

Comparison basis: Ranked among 22 of 31 funds · 9 left out (4 missing return, 2 return as of an earlier date, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026

5 years (ann.)

Comparison basis: Ranked among 22 of 31 funds · 9 left out (4 missing return, 2 return as of an earlier date, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026

The positions describe historical return and are not an assessment of the fund, nor investment advice. Past performance is no guarantee of future returns. A position applies only within its own peer group and cannot be compared with positions in other peer groups.

Fund data is taken from the managers’ own reports, otherwise computed from NAV history and, as a last resort, taken from distributor listings. Not official figures; verify with the fund provider before investing.

About our data